Press Releases on December 6, 2015 - EIN Presswire - Press Release Distribution Service

Published on December 6, 2015 - 23:00 GMT

MediciNova Announces Presentation Regarding Clinical Trial of MN-166 (ibudilast) in ALS at the 6th Annual California ALS Pac10 and ...

LA JOLLA, Calif., Dec. 06, 2015 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number:4875), announced that Dr. Yuichi Iwaki, …

Distribution channels: Conferences & Trade Fairs, Healthcare & Pharmaceuticals Industry ...

Published on December 6, 2015 - 23:00 GMT

TG Therapeutics, Inc. Announces Data Presentations at the 57th American Society of Hematology Annual Meeting From Ongoing Clinical ...

Combination of TG-1101 plus TGR-1202 (“TG-1303”) continues to demonstrate a favorable safety profile, with only 8% of patients discontinuing due to an adverse event and no cases of colitis reported to date 80% (8 of 10) ORR in patients with relapsed …

Distribution channels: Conferences & Trade Fairs, Technology

Published on December 6, 2015 - 22:34 GMT

Aerojet Rocketdyne Propulsion Helps Deliver Resupply Mission to International Space Station

SACRAMENTO, Calif., Dec. 6, 2015 (GLOBE NEWSWIRE) -- Aerojet Rocketdyne, a subsidiary of Aerojet Rocketdyne Holdings, Inc. (NYSE:AJRD), helped propel the Orbital ATK Cygnus cargo spacecraft today on its fourth operational cargo delivery flight, …

Distribution channels: Aviation & Aerospace Industry

Published on December 6, 2015 - 21:43 GMT

Talks to Diplomatic Consular Corps of Karnataka and at National Institute of Advanced Studies

Bengaluru, Karnataka, India, 6 December 2015 - This morning in Bengaluru His Holiness the Dalai Lama was the guest of the Diplomatic Consular Corps of Karnataka, He was welcomed to the platform by Anatole Kuschpeta from France and invited to participate in …

Distribution channels: Religion

Published on December 6, 2015 - 21:31 GMT

Agios Announces Data from Ongoing Phase 1/2 Trial of AG-221 Showing Durable Responses in Patients with Advanced Hematologic ...

- Patients on Study for up to 18 Months with a Median Response Duration of 6.9 Months in Relapsed/Refractory Acute Myeloid Leukemia (AML) - - Enrollment Complete for Four 25-Patient Expansion Cohorts; 125-Patient Expansion Cohort and Phase 3 IDHENTIFY …

Distribution channels: Banking, Finance & Investment Industry, Conferences & Trade Fairs ...

Published on December 6, 2015 - 18:15 GMT

Curis Reports Clinical Activity of CUDC-907 in Patients With DLBCL Harboring MYC Oncogene Alterations at the 2015 ASH Annual ...

CUDC-907 (HDAC and PI3K inhibitor) demonstrates objective responses, including complete responses, in patients with relapsed/ refractory DLBCL with MYC alterations Curis expects to initiate a randomized Phase 2 trial in patients with relapsed/ …

Distribution channels: Banking, Finance & Investment Industry, Technology

Published on December 6, 2015 - 16:07 GMT

Statement by the Prime Minister on the National Day of Remembrance and Action on Violence Against Women

OTTAWA, ONTARIO -- (Marketwired) -- 12/06/15 -- The Prime Minister, Justin Trudeau, today issued the following statement on the National Day of Remembrance and Action on Violence Against Women: "Today, it is important for us to reflect on all of the …

Distribution channels: U.S. Politics

Published on December 6, 2015 - 15:26 GMT

Calithera Biosciences Reports Phase I Data for CB-839 in Patients With Hematological Malignancies at the 57th American Society of ...

First results of CB-839 dosed in combination therapy Promising clinical activity with early signs of biologic activity, tolerability, and durability SOUTH SAN FRANCISCO, Calif., Dec. 06, 2015 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq:CALA), a …

Distribution channels: Conferences & Trade Fairs, Technology